Quiver Newsquiverquant.comQuiver News

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids

Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of patients, from infants to elderly people

TARRYTOWN, N.Y. and PARIS, June 20, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent

^®

(dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).

BP primarily affects elderly patients, and is characterized by intense itch, painful blisters and lesions, as well as reddening of the skin. It can be chronic and relapsing with underlying type 2 inflammation. The blisters and rash can form over much of the body and cause the skin to bleed and break down, resulting in patients being more prone to infection and affecting their daily functioning. Available treatment options are limited and can add to overall disease burden by suppressing a patient’s immune system.

“People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available, with potential side effects that have often added to their burden,” Patrick Dunn, Executive Director at the International Pemphigus and Pemphigoid Foundation. “The approval of Dupixent for bullous pemphigoid brings a novel treatment approach to patients and their caregivers, and we are grateful for the tireless efforts of the scientific community who helped us reach this critical milestone.”

“Today’s approval extends the remarkable ability of Dupixent to transform treatment paradigms for people living with a variety of diseases with underlying type 2 inflammation, from common conditions like asthma and atopic dermatitis, to rarer ones such as eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Dupixent has shown the potential to improve the most challenging effects of bullous pemphigoid, while helping some patients achieve sustained disease remission and decreased oral corticosteroid use. Additionally, this approval further reinforces the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and across dermatological, respiratory and gastrointestinal diseases.”

The FDA approval is based on data from the pivotal ADEPT Phase 2/3 trial that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP. Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. During the FDA review, the analyses were updated; the FDA-approved results at 36 weeks in the label for Dupixent compared to placebo are:

• 18.3% of patients experienced sustained disease remission compared to 6.1% (12.2% difference; 95% confidence interval: -0.8% to 26.1%), the primary endpoint
• 38.3% of patients achieved clinically meaningful itch reduction compared to 10.5%
• Median cumulative OCS dose was 2.8 grams compared to 4.1 grams
  

In this elderly population, the most common adverse events (≥2%) more frequently observed in patients on Dupixent compared to placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections and keratitis. Additionally, 1 case of acute generalized exanthematous pustulosis was reported in 1 patient treated with Dupixent and 0 patients treated with placebo.

“Until now, treating bullous pemphigoid was very challenging for elderly patients struggling with the debilitating impact of blisters and lesions, and potentially co-morbid conditions,” said Alyssa Johnsen, M.D., Ph.D., Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. “By addressing two central drivers of the underlying type 2 inflammation that contributes to bullous pemphigoid, Dupixent is the first targeted medicine to allow patients the potential to achieve sustained remission and reduce itch. This approval in the U.S. is important for the thousands of patients living with bullous pemphigoid, and we look forward to working with regulators around the world to bring this innovative medicine to more patients in need.”

The FDA evaluated Dupixent under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions. Dupixent was previously granted Orphan Drug Designation by the FDA for BP, which applies to investigational medicines intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. Additional regulatory applications are also under review around the world, including in the EU, Japan and China.

About the Dupixent BP Pivotal Trial


ADEPT was a randomized, Phase 2/3, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP for a 52-week treatment period. After randomization, patients received Dupixent or placebo every two weeks after an initial loading dose, along with OCS treatment. During treatment, OCS taper was initiated after patients experienced two weeks of sustained control of disease activity. OCS tapering could start between four to six weeks after randomization and was continued if disease control was maintained, with the intent of completion by 16 weeks. After OCS tapering, patients were only treated with Dupixent or placebo for at least 20 weeks (rescue treatment could be used if required).

The primary endpoint evaluated the proportion of patients achieving sustained disease remission at 36 weeks. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by 16 weeks without relapse after completion of the OCS taper and no rescue therapy use during the 36-week treatment period. Relapse was defined as appearance of ≥3 new lesions a month or ≥1 large lesion or urticarial plaque (>10 cm in diameter) that did not heal within a week. Rescue therapy could include treatment with high-potency topical corticosteroids, OCS (including increase of OCS dose during the taper or re-initiation of OCS after completion of the OCS taper), or systemic non-steroidal immunosuppressive medications or immunomodulating biologics.

Select secondary endpoints evaluated at 36 weeks included:

• Proportion of patients with ≥4-point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS; scale 0-10)
• Total cumulative OCS dose

About Dupixent


Dupixent is an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with BP, Dupixent 300 mg is administered every other week after an initial loading dose, and in combination with a tapering course of oral corticosteroids. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional.

Dupixent, which was invented using Regeneron’s proprietary

VelocImmune


^®


technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT

MyWay


^®


program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit

www.DUPIXENT.com

.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU), chronic obstructive pulmonary disease (COPD) and BP in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.

¹

About Regeneron’s



VelocImmune



Technology


Regeneron’s

VelocImmune

technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron’s co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to

envision

making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing

VelocImmune

and related

VelociSuite


^®

technologies. Dr. Yancopoulos and his team have used

VelocImmune

technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent

^®

(dupilumab), Libtayo

^®

(cemiplimab-rwlc), Praluent

^®

(alirocumab), Kevzara

^®

(sarilumab), Evkeeza

^®

(evinacumab-dgnb), Inmazeb

^®

(atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz

^®

(pozelimab-bbfg). In addition, REGEN-COV

^®

(casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.

Dupilumab Development Program


Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.

U.S. INDICATIONS


DUPIXENT is a prescription medicine used:

• to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with AD under 6 months of age.
• with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.
• with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with CRSwNP under 12 years of age.
• to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with EoE under 1 year of age, or who weigh less than 33 pounds (15 kg).
• to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with PN under 18 years of age.
• with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with COPD under 18 years of age.
• to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with CSU under 12 years of age, or who weigh less than 66 pounds (30 kg).
• to treat adults with bullous pemphigoid (BP). It is not known if DUPIXENT is safe and effective in children with BP under 18 years of age.

DUPIXENT is not used

to relieve sudden breathing problems and will not replace an inhaled rescue medicine

or

to treat any other forms of hives (urticaria).

IMPORTANT SAFETY INFORMATION

Do not use

if you are allergic to dupilumab or to any of the ingredients in DUPIXENT

^®

.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

• have eye problems.
• have a parasitic (helminth) infection.
• are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.
• are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
  • A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to
    
    https://mothertobaby.org/ongoing-study/dupixent/
    
    .
• are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you

are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have AD, CRSwNP, EoE, PN, COPD, CSU, or BP and also have asthma.

Do not

change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

• 
  Allergic reactions. DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe.
  
  Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye, painful red or blue bumps under the skin, or red pus-filled spots on the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.
• 
  Eye
  
  
  pr
  
  
  ob
  
  
  l
  
  
  e
  
  
  m
  
  
  s.
  
  Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.
• 
  I
  
  
  n
  
  
  fl
  
  
  a
  
  
  mm
  
  
  a
  
  
  t
  
  
  i
  
  
  o
  
  
  n
  
  
  o
  
  
  f
  
  
  y
  
  
  ou
  
  
  r
  
  
  b
  
  
  l
  
  
  oo
  
  
  d
  
  
  v
  
  
  e
  
  
  ss
  
  
  e
  
  
  l
  
  
  s.
  
  Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you get: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.
• 
  Psoriasis.
  
  This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.
• 
  Joint aches and pain.
  
  Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.
  

The most common side effects include:

• 
  Eczema:
  
  injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, dry eye, and blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).
• 
  A
  
  
  s
  
  
  t
  
  
  h
  
  
  ma:
  
  injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.
• 
  Chronic Rhinosinusitis with Nasal Polyps:
  
  injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache.
• 
  Eosinophilic Esophagitis:
  
  injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).
• 
  Prurigo Nodularis:
  
  eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.
• 
  Chronic Obstructive Pulmonary Disease:
  
  injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, stomach problems (gastritis), joint pain (arthralgia), toothache, headache, and urinary tract infection.
• 
  Chronic Spontaneous Urticaria:
  
  injection site reactions.
• 
  Bullous Pemphigoid:
  
  joint pain (arthralgia), eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, and herpes virus infections.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit

www.fda.gov/medwatch

, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT.

Do not

try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

P


l


ea


se


s


e


e


a


cc


o


mp


any


i


n


g


f


u


l


l



P


r


e


s


cri


b


i


n


g


I


n


f


o


r


ma


t


i


o


n



i


nc


l


ud


i


n


g


P


a


t


i


en


t


I


n


f


o


r


ma


t


i


o


n.

About Regeneron


Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as

VelociSuite,

which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center

^®

and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit

www.Regeneron.com

or follow Regeneron on

LinkedIn

,

Instagram

,

Facebook

or

X

.

About Sanofi


Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Regeneron Forward-Looking Statements and Use of Digital Media



This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent


^®


(dupilumab)


for the treatment of bullous pemphigoid as discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, and other potential indications; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA


^®


(aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Sanofi Disclaimers or Forward-Looking Statements



This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group except for

VelociSuite

and

Regeneron Genetics Center

.

¹

Data on File

SINGAPORE, June 19, 2025 (GLOBE NEWSWIRE) — OMS Energy Technologies Inc. (“OMS” or the “Company”) (Nasdaq: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today provided a business update outlining its recent accomplishments as the Company prepares for its inaugural earnings call following its successful Nasdaq listing in May 2025.

Operational Highlights

• New order win in Angola and renewed contract in Thailand; Southeast Asia emerging as driving force in customer acquisition
• Expanding business footprint and growing talent pool
• R&D achievements and partnerships steadily enriching product portfolio
• Consistent enhancements to occupational health, safety and environmental management
• Development initiatives fostering revenue diversification and enhancing financial stability
  

Mr. How Meng Hock, CEO of OMS Energy Technologies Inc., commented, “We’re excited to begin our journey as a public company with a healthy operational foundation, underscored by thriving customer relationships and partnerships, an expanding brand presence and cutting-edge R&D and manufacturing capabilities. We are also supported by a strong balance sheet and a deep commitment to prudent financial management, positioning us to quickly and flexibly execute our development strategy when suitable opportunities arise. With our focus on exceptional service and dedication to crafting superior products, we’re confident of delivering innovative solutions to a growing, global customer base, creating value for all of our stakeholders.”

Customer Growth and Diversification

Offering a broad array of highly engineered products and customizable solutions for the oil and gas industry, OMS is anchored by a solid base of long-term contracts and longstanding relationships with global and local oil companies, drilling contractors, E&P and oilfield service providers across the Asia Pacific, Middle East and North Africa (MENA), and West African regions. The Company recently entered the Angola market and has secured a letter of award through its Middle East representative for the supply of surface wellhead systems to Grupo Simples Oil in the Onshore Kwanza Basin Block of KON-06 in Angola, expanding its brand presence in West Africa.

In the Indonesian market, the Company’s marketing efforts are attracting new customers, such as PT Seleraya Belida (South Sumatra) and Pertamina Hulu Sanga Sanga (East Kalimantan), and driving steady growth in sales of surface wellhead and Christmas tree products.

OMS’ existing customer base continues to exhibit strong loyalty. In June, PTTEP, a long-term customer in the Thailand market, signed a new three-year agreement effective July 1, 2025, further stabilizing the Company’s revenue base. The Company also inked a 10-year supply agreement with Saudi Aramco in early 2024, projected to generate an estimated $120 to $200 million annually. Moreover, the Company’s annual price agreement with Halliburton continues to fuel robust order volumes at its Malaysia and Singapore facilities.

Geographic and Talent Pool Expansion

OMS boasts a broad geographic footprint in the oil-rich Asia Pacific and MENA regions, with 11 manufacturing facilities strategically situated across six countries (Singapore, Malaysia, Brunei, Saudi Arabia, Thailand, and Indonesia). By hiring local citizens, producing products and services within these jurisdictions, and sourcing high-value materials locally, the Company establishes eligibility to participate in government tenders and contracts, boosting its competitive edge. Employing locals also helps the Company meet the requirements of localization programs such as IKTVA in Saudi Arabia and TKDN in Indonesia while enriching its talent pool. The Company is exploring new operating jurisdictions to increase market share and extending its reach globally through a growing number of export countries.

Product Development & Manufacturing Advancements

OMS’s $1.1 million investment in Additive Manufacturing (AM) research is propelling progress in the development of a metallic seal for the Company’s high-pressure-high temperature (HPHT) gate valves, a technological breakthrough that promises to promote innovation, improve supply chain efficiency and enable better material selection for critical components. To date, OMS has completed Phase 1 of its proof of concept, covering material selection, additive manufacturing methodology and stress analysis on the part for fit, form and function for using this method. The Company continues to invest in R&D, forging partnerships with top institutions such as the Singapore Institute of Manufacturing and Technology (SIMTech) to remain at the forefront of industry innovation.

Meanwhile, the Company is steadily delivering on orders placed under its long-term agreements with Saudi Aramco and Halliburton Malaysia and Singapore, leveraging its precision manufacturing expertise and strategically-located facilities to produce mission-critical products and custom solutions with shorter lead times. A healthy, balanced manufacturing capacity utilization level empowers OMS to seamlessly meet rising demand from new and existing customers.

Occupational Health, Safety and Environmental Management Enhancements

Safety and environmental protection are critical to the oil and gas industry and a key cornerstone of OMS’ operations. The Company holds ISO 9001 and API Q1 quality management system certifications for all of its manufacturing sites, as well as ISO 45001-Occupational Health and Safety Management System and ISO 14001-Environmental Management System certifications. The Company recently completed the annual surveillance audit required to maintain its ISO 45001 and ISO 14001 certifications, a crucial step in the Company’s ongoing implementation of ESG programs.

Strategic Development Initiatives

Sustainable, long-term growth remains OMS’ top priority. The Company’s R&D collaboration with Singapore’s Agency for Science, Technology and Research (A*STAR) and SIMTech reflects its commitment to environmental sustainability, covering life cycle analysis, energy efficiency monitoring and digital transformation and innovation. OMS is also actively exploring growth and revenue diversification through acquisitions, joint ventures and strategic alliances. By driving development both organically and externally, OMS is creating a more resilient and balanced portfolio, strengthening the backbone of its business.

About


OMS Energy Technologies Inc.

OMS Energy Technologies Inc. (NASDAQ: OMSE) is a growth-oriented manufacturer of surface wellhead systems (SWS) and oil country tubular goods (OCTG) for the oil and gas industry. Serving both onshore and offshore exploration and production operators, OMS is a trusted single-source supplier across six vital jurisdictions in the Asia Pacific, Middle Eastern and North African (MENA) regions. The Company’s 11 strategically located manufacturing facilities in key markets ensure rapid response times, customized technical solutions and seamless adaptation to evolving production and logistics needs. Beyond its core SWS and OCTG offerings, OMS also provides premium threading services to maximize operational efficiency for its customers.

For more information, please visit

ir.omsos.com

.

Forward-Looking


Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or our future financial or operating performance and include statements regarding the expected size, timing and results of the initial public offering. When used in this press release, words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “budget,” “plan,” “seek,” “envision,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” as well as the negative of these terms and similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in OMS’s prospectus. OMS undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

For investor and media inquiries, please contact:

OMS Energy Technologies Inc.

Investor Relations

Email:

[email protected]

Piacente Financial Communications

Brandi Piacente

Tel: +1-212-481-2050

Email:

[email protected]

Hui Fan

Tel: +86-10-6508-0677

Email:

[email protected]

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Performance restricted stock units (“PRSUs”)

Restricted stock units (“RSUs”)

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO

^®

(esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.

¹

Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit


NeuroStar.com


.

Neuronetics Contact:

Investors:

Mike Vallie or Mark Klausner

ICR Healthcare

443-213-0499



[email protected]



Media:

EvolveMKD

646.517.4220



[email protected]

¹

The effectiveness of SPRAVATO

^®

in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO

^®

does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO

^®

. For more important safety information about SPRAVATO

^®

, please visit


spravatohcp.com


.

BETHESDA, Md., June 19, 2025 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ: LQDT; www.liquidityservices.com), a leading global commerce company powering the circular economy, today announced that Paul J. Hennessy has been appointed to the company’s board of directors (the “Board”) effective October 1, 2025. Mr. Hennessy will also serve on the Corporate Governance and Nominating Committee and the Audit Committee of the Board.

“We are thrilled to welcome Paul to our Board of Directors,” said Bill Angrick, Chairman and CEO of Liquidity Services. “Paul’s deep knowledge and extensive experience building technology enabled marketplaces in both business and consumer channels on a global scale will be instrumental as we continue to expand our market presence, enhance our service offerings, and pursue emerging opportunities to drive long-term growth.”

Mr. Hennessy is an experienced CEO with over 30 years of leadership experience focused on growing and optimizing innovative, market leading technology and marketplace businesses. He has served as the Chief Executive Officer of Shutterstock, Inc. (NYSE: SSTK) since July 2022 and as a member of Shutterstock’s board of directors since April 2015. From June 2016 to May 2022, Mr. Hennessy served as Chief Executive Officer and member of the board of directors of Vroom, Inc., a provider of AI-powered analytics, financing and digital services for automotive dealers and consumers of pre-owned vehicles. Prior to joining Vroom, from April 2015 through June 2016, Mr. Hennessy served as Chief Executive Officer of Priceline.com, a pioneer in online travel and travel related reservation and search services. From November 2011 to March 2015, Mr. Hennessy served as Chief Marketing Officer of Booking.com, an online booking accommodations provider. From July 2006 to October 2011, Mr. Hennessy was Chief Distribution Officer of Priceline.com. Mr. Hennessy holds a B.S. in marketing management from Dominican College and an M.B.A. from Long Island University.

“I am honored to join the Board of Liquidity Services,” said Hennessy. “I look forward to working with the leadership team to advance the company’s strategic priorities and contribute to its ongoing success and innovation as the market leader powering the circular economy.”

About Liquidity Services

Liquidity Services (NASDAQ: LQDT) operates the world’s largest B2B e-commerce marketplace platform for surplus assets with over $10 billion in completed transactions to more than five million qualified buyers and 15,000 corporate and government sellers worldwide. The company supports its clients’ sustainability efforts by helping them extend the life of assets, prevent unnecessary waste and carbon emissions, and reduce the number of products headed to landfills.

Contact:


Investor Relations


[email protected]

SAN JUAN CAPISTRANO, Calif., June 19, 2025 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0625 per share of Ensign common stock, payable on or before July 31, 2025, to shareholders of record as of June 30, 2025.

Ensign has been a dividend-paying company since 2002.

About Ensign ™

The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 347 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at

http://www.ensigngroup.net


.

Contact Information

The Ensign Group, Inc., (949) 487-9500, [email protected]

SOURCE: The Ensign Group, Inc.

MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) announced today that its industry-leading


Falcon Premium


intermodal service has received the

Silver Container (Contenedor de Plata)

award from the

Asociación Mexicana del Transporte Intermodal (AMTI)

. AMTI is Mexico’s leading intermodal transport association, representing key stakeholders across the industry and promoting best practices in cross-border logistics. This prestigious award recognizes outstanding achievements in cross-border intermodal transportation between Mexico, the United States, and Canada.

“We are honored to receive AMTI’s Silver Container Award for our Falcon Premium service. CN is proud to lead the way in delivering a seamless, all-rail interline service that reflects our commitment to innovation, exceptional customer service, and sustainability across the North American supply chain.”

– Derek Taylor, Executive Vice-President and Chief Field Operating Officer at CN

“Falcon Premium is the industry standard, providing customers truck-like service reliability for their shipments from Mexico through the United States to Canada. We’re honored to receive this recognition and proud to collaborate with CN and GMXT to provide customers a winning solution that takes trucks off congested highways and reduces greenhouse gas emissions by up to 75%.”

– Kenny Rocker, Executive Vice President – Marketing & Sales at Union Pacific

“GMXT will always strive to be at the forefront of its service. Falcon Premium is becoming one of the most efficient means to reach North America in a sustainable way. We will continue working hand in hand with CN and UP on projects like this one.”

– Luis Hernández, Vice President Intermodal at GMXT

CN developed the Falcon Premium intermodal service in close collaboration with

Union Pacific (UP)

and

Grupo México Transportes (GMXT)

. Together, the railroads deliver the fastest and most seamless all-rail interline service connecting

Canada, the U.S. Midwest, and Mexico

.

Falcon Premium helps customers move freight with greater speed, reliability, and environmental efficiency. By eliminating truck interchanges and optimizing route mileage, the service offers the most direct and fuel-efficient rail connection between Canada and Mexico—accelerating speed-to-market while lowering emissions.

The Silver Container Award highlights Falcon Premium’s transformative impact on intermodal shipping and underscores CN’s broader mission to build smarter, greener, and more resilient transportation networks.

To learn more about the award, visit:

https://www.amti.org.mx/contenedor-de-plata

CN Forward-Looking Statements


Certain statements by CN included in this news release constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and under Canadian securities laws. By their nature, forward-looking statements involve risks, uncertainties and assumptions. CN cautions that its assumptions may not materialize and that current economic conditions render such assumptions, although reasonable at the time they were made, subject to greater uncertainty. Forward-looking statements may be identified by the use of terminology such as “believes,” “expects,” “anticipates,” “assumes,” “outlook,” “plans,” “targets,” or other similar words. Forward-looking statements reflect information as of the date on which they are made. CN assumes no obligation to update or revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, unless required by applicable securities laws. In the event CN does update any forward-looking statement, no inference should be made that CN will make additional updates with respect to that statement, related matters, or any other forward-looking statement.

About CN


CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts:

WHITE PLAINS, N.Y., June 19, 2025 (GLOBE NEWSWIRE) — NorthEast Community Bancorp, Inc. (the “Company”) (Nasdaq: NECB) announced today that its Board of Directors has declared a quarterly cash dividend of $0.20 per common share. The dividend will be paid on or about August 6, 2025 to shareholders of record as of the close of business on July 7, 2025.

About NorthEast Community Bancorp, Inc.

NorthEast Community Bancorp, headquartered at 325 Hamilton Avenue, White Plains, New York 10601, is the holding company for NorthEast Community Bank, which conducts business through its eleven branch offices located in Bronx, New York, Orange, Rockland, and Sullivan Counties in New York and Essex, Middlesex, and Norfolk Counties in Massachusetts and three loan production offices located in New City, New York, White Plains, New York, and Danvers, Massachusetts. For more information about NorthEast Community Bancorp and NorthEast Community Bank, please visit

www.necb.com

.

Cautionary Note About Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements include statements regarding anticipated future events and can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believe,” “expect,” “anticipate,” “estimate,” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause actual results to differ materially from expected results include, but are not limited to, changes in market interest rates, regional and national economic conditions (including higher inflation and its impact on regional and national economic conditions), legislative and regulatory changes, monetary and fiscal policies of the United States government, including policies of the United States Treasury and the Federal Reserve Board, the quality and composition of the loan or investment portfolios, demand for loan products, decreases in deposit levels necessitating increased borrowing to fund loans and securities, competition, demand for financial services in NorthEast Community Bank’s market area, changes in the real estate market values in NorthEast Community Bank’s market area, the impact of failures or disruptions in or breaches of the Company’s operational or security systems, data or infrastructure, or those of third parties, including as a result of cyberattacks or campaigns, and changes in relevant accounting principles and guidelines. Additionally, other risks and uncertainties may be described in our annual and quarterly reports filed with the U.S. Securities and Exchange Commission (the “SEC”), which are available through the SEC’s website located at www.sec.gov. These risks and uncertainties should be considered in evaluating any forward-looking statements and undue reliance should not be placed on such statements. Except as required by applicable law or regulation, the Company does not undertake, and specifically disclaims any obligation, to release publicly the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of the statements or to reflect the occurrence of anticipated or unanticipated events.

QUEBEC CITY, June 19, 2025 (GLOBE NEWSWIRE) —

LeddarTech



^®


Holdings Inc.

(“LeddarTech” or the “Company”) (


Nasdaq: LDTC


), an AI-powered software company recognized for its innovation in advanced driver assistance systems (ADAS) and autonomous driving (AD), today announces that on June 17, 2025, the Company received a determination letter (the “Determination Letter”) from Nasdaq notifying the Company that Nasdaq has determined that, in accordance with its authority under Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Company’s securities will be suspended from trading at the opening of business on June 24, 2025 and delisted from Nasdaq.

Nasdaq based its determination upon concerns related to (i) the Company’s announcement of its intention to file under the

Bankruptcy and Insolvency Act

(Canada) (the “BIA”) and the associated public interest concerns raised by such filing, (ii) the residual equity interest of the existing listed securities holders, and (iii) the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq.

The Determination Letter also advises the Company of its right to request an appeal of the determination. However, the Company currently does not intend to file an appeal of the determination. Accordingly, the Company expects that its securities will be suspended from trading at the opening of business on June 24, 2025 and delisted from Nasdaq after the completion of Nasdaq’s filing of Form 25-NSE with the Securities and Exchange Commission.

Filing under the BIA

Further to its press release dated June 16, 2025, the Company announces having filed under the BIA on June 18, 2025. As a result of such filing, the board of directors of the Company has resigned effective as of such date.

Additional information with respect to the BIA proceedings will be available in due course on Raymond Chabot Inc.’s website.

About


LeddarTech

A global software company founded in 2007 and headquartered in Quebec City with additional R&D centers in Montreal and Tel Aviv, Israel, LeddarTech develops and provides comprehensive AI-based low-level sensor fusion and perception software solutions that enable the deployment of ADAS, autonomous driving (AD) and parking applications. LeddarTech’s automotive-grade software applies advanced AI and computer vision algorithms to generate accurate 3D models of the environment to achieve better decision making and safer navigation. This high-performance, scalable, cost-effective technology is available to OEMs and Tier 1-2 suppliers to efficiently implement automotive and off- road vehicle ADAS solutions.

LeddarTech is responsible for several remote-sensing innovations, with over 190 patent applications (112 granted) that enhance ADAS, AD and parking capabilities. Better awareness around the vehicle is critical in making global mobility safer, more efficient, sustainable and affordable: this is what drives LeddarTech to seek to become the most widely adopted sensor fusion and perception software solution.

Additional information about LeddarTech is accessible at


www.leddartech.com


and on


LinkedIn

,



Twitter


(X)

,



Facebook


and


YouTube


.

Forward-Looking


Statements

Certain statements contained in this Press Release may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which forward-looking statements also include forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws). Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend” and other similar expressions among others. Forward-looking statements in this press release include, without limitation, statements regarding the BIA proceedings. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties, including the risk factors as detailed from time to time in LeddarTech’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including the risk factors contained in LeddarTech’s Form 20-F filed with the SEC. The foregoing list of important factors is not exhaustive. Except as required by applicable law, LeddarTech does not undertake any obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision and related logos are trademarks or


registered


trademarks


of


LeddarTech


Holdings


Inc.


and its


subsidiaries.


All


other


brands,


product


names


and


marks are or may be trademarks or registered trademarks used to


identify products or services of their respective


o


w


ners.

LeddarTech


Holdings


Inc.


is


a


public


company


listed


on


the


Nasdaq


under


the


ticker


symbol


“LDTC.”

COLUMBUS, Ohio, June 19, 2025 (GLOBE NEWSWIRE) —


Worthington Enterprises


(NYSE: WOR), a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences, today announced its acquisition of


Elgen Manufacturing


(Elgen) of Closter, New Jersey. Elgen is a market-leading designer and manufacturer of HVAC parts and components, ductwork and structural framing primarily used in commercial buildings throughout North America. Recurring demand for maintenance, repair and remodel of existing HVAC installations is a key driver of volume and customer spend in these markets.

Joe Hayek, president and chief executive officer, Worthington Enterprises, said, “The addition of Elgen aligns closely with our strategy to build and acquire businesses with leadership positions in niche markets. Elgen’s manufacturing processes, go-to-market strategies and end markets mirror ours, creating meaningful opportunities for synergies and growth. We are excited to welcome the Elgen team to Worthington Enterprises and look forward to growing together as their 250 employees become part of our people-first, performance-based culture.”

Elgen will become part of the


Building Products segment at Worthington Enterprises


that includes a portfolio of critical building systems and components for heating, cooling, construction and water applications, as well as architectural and acoustical grid ceilings and metal framing and accessories. Elgen’s steel-based products are used by contractors to renovate, repair and build the HVAC infrastructure within commercial buildings. Its sales strategy features direct sales to contractors and strategic distributor partnerships that broaden reach into niche markets. The company’s distribution model allows for superior customer service and flexibility in best-in-class lead times for specialty (non-standard) products that are frequently needed by contractors installing on tight timelines.

Jimmy Bowes, president, Building Products, Worthington Enterprises, added, “Elgen’s HVAC componentry and recurring revenue through maintenance, repair and remodel are a natural fit with our products for the building envelope. We believe we can create new value for Elgen’s customers and generate operational efficiencies for the business by leveraging Worthington’s domestic footprint, manufacturing expertise and purchasing power.”

David Young, chief executive officer, Elgen Manufacturing, said, “This is a milestone in our rich history and one that we believe accelerates our ability to serve our customers and retain and attract a top workforce. We look forward to supporting the continued growth of Worthington Enterprises and remain committed to delivering innovative products and excellent service to our customers.”

Young and other members of the Elgen leadership team will remain with the business and maintain similar roles and responsibilities.

Worthington Enterprises acquired Elgen Manufacturing for approximately $93 million funded with cash on hand. For the trailing 12 months ended April 30, 2025, Elgen generated net sales of $114.9 million and EBITDA of $13.3 million.

A presentation with more information on the transaction can be found on the


investor relations section of the Company’s website


.

About Worthington Enterprises


Worthington Enterprises (NYSE: WOR) is a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences. The Company operates with two primary business segments: Building Products and Consumer Products. The Building Products segment includes cooking, heating, cooling and water solutions, architectural and acoustical grid ceilings and metal framing and accessories. The Consumer Products segment provides solutions for the tools, outdoor living and celebrations categories. Product brands within the Worthington Enterprises portfolio include Balloon Time®, Bernzomatic®, Coleman® (propane cylinders), CoMet®, Elgen, Garden Weasel®, General®, HALO™, Hawkeye™, Level5 Tools®, Mag Torch®, NEXI™, Pactool International®, PowerCore™, Ragasco®, Well-X-Trol® and XLite™, among others.

Headquartered in Columbus, Ohio, Worthington Enterprises and its joint ventures employ approximately 6,000 people throughout North America and Europe.

Founded in 1955 as Worthington Industries, Worthington Enterprises follows a people-first Philosophy with earning money for its shareholders as its first corporate goal. Worthington Enterprises achieves this outcome by empowering its employees to innovate, thrive and grow with leading brands in attractive markets that improve everyday life. The Company engages deeply with local communities where it has operations through volunteer efforts and


The Worthington Companies Foundation


, participates actively in


workforce development programs


and reports annually on its


corporate citizenship and sustainability efforts


. For more information, visit


worthingtonenterprises.com


.

Safe Harbor Statement


Selected statements contained in this release constitute “forward-looking statements,” as that term is used in the Private Securities Litigation Reform Act of 1995 (the “Act”). The Company wishes to take advantage of the safe harbor provisions included in the Act. Forward-looking statements reflect the Company’s current expectations, estimates or projections concerning future results or events. These statements are often identified by the use of forward-looking words or phrases such as “believe,” “expect,” “anticipate,” “may,” “could,” “should,” “would,” “intend,” “plan,” “will,” “likely,” “estimate,” “project,” “position,” “strategy,” “target,” “aim,” “seek,” “foresee” and similar words or phrases. These forward-looking statements include, without limitation, statements relating to: future or expected cash positions, liquidity and ability to access financial markets and capital; outlook, strategy or business plans; the anticipated benefits of the separation of the Company’s Steel Processing business (the “Separation); the expected financial and operational performance of, and future opportunities for, the Company following the Separation; the Company’s performance on a pro forma basis to illustrate the estimated effects of the Separation on historical periods; the tax treatment of the Separation transaction; future or expected growth, growth potential, forward momentum, performance, competitive position, sales, volumes, cash flows, earnings, margins, balance sheet strengths, debt, financial condition or other financial measures; pricing trends for raw materials and finished goods and the impact of pricing changes; the ability to improve or maintain margins; expected demand or demand trends for the Company or its markets; additions to product lines and opportunities to participate in new markets; expected benefits from transformation and innovation efforts; the ability to improve performance and competitive position at the Company’s operations; anticipated working capital needs, capital expenditures and asset sales; anticipated improvements and efficiencies in costs, operations, sales, inventory management, sourcing and the supply chain and the results thereof; projected profitability potential; the ability to make acquisitions and the projected timing, results, benefits, costs, charges and expenditures related to acquisitions, joint ventures, headcount reductions and facility dispositions, shutdowns and consolidations; projected capacity and the alignment of operations with demand; the ability to operate profitably and generate cash in down markets; the ability to capture and maintain market share and to develop or take advantage of future opportunities, customer initiatives, new businesses, new products and new markets; expectations for Company and customer inventories, jobs and orders; expectations for the economy and markets or improvements therein; expectations for generating improving and sustainable earnings, earnings potential, margins or shareholder value; effects of judicial rulings; the ever-changing effects of the novel coronavirus (“COVID-19”) pandemic and the various responses of governmental and nongovernmental authorities thereto on economies and markets, and on our customers, counterparties, employees and third-party service providers; and other non-historical matters.

Because they are based on beliefs, estimates and assumptions, forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those projected. Any number of factors could affect actual results, including, without limitation, those that follow: the uncertainty of obtaining regulatory approvals in connection with the Separation, including rulings from the Internal Revenue Service; the Company’s ability to successfully realize the anticipated benefits of the Separation; the risks, uncertainties and impacts related to the COVID-19 pandemic – the duration, extent and severity of which are impossible to predict, including the possibility of future resurgence in the spread of COVID-19 or variants thereof – and the availability, effectiveness and acceptance of vaccines, and other actual or potential public health emergencies and actions taken by governmental authorities or others in connection therewith; the effect of national, regional and global economic conditions generally and within major product markets, including significant economic disruptions from COVID-19, the actions taken in connection therewith and the implementation of related fiscal stimulus packages; the effect of conditions in national and worldwide financial markets, including inflation, increases in interest rates and economic recession, and with respect to the ability of financial institutions to provide capital; the impact of tariffs, the adoption of trade restrictions affecting the Company’s products or suppliers, a United States withdrawal from or significant renegotiation of trade agreements, the occurrence of trade wars, the closing of border crossings, and other changes in trade regulations or relationships; changing oil prices and/or supply; product demand and pricing; changes in product mix, product substitution and market acceptance of the Company’s products; volatility or fluctuations in the pricing, quality or availability of raw materials (particularly steel), supplies, transportation, utilities, labor and other items required by operations (especially in light of the COVID-19 pandemic and Russia’s invasion of Ukraine); effects of sourcing and supply chain constraints; the outcome of adverse claims experience with respect to workers’ compensation, product recalls or product liability, casualty events or other matters; effects of facility closures and the consolidation of operations; the effect of financial difficulties, consolidation and other changes within the steel, automotive, construction and other industries in which the Company participates; failure to maintain appropriate levels of inventories; financial difficulties (including bankruptcy filings) of original equipment manufacturers, end-users and customers, suppliers, joint venture partners and others with whom the Company does business; the ability to realize targeted expense reductions from headcount reductions, facility closures and other cost reduction efforts; the ability to realize cost savings and operational, sales and sourcing improvements and efficiencies, and other expected benefits from transformation initiatives, on a timely basis; the overall success of, and the ability to integrate, newly-acquired businesses and joint ventures, maintain and develop their customers, and achieve synergies and other expected benefits and cost savings therefrom; capacity levels and efficiencies, within facilities, within major product markets and within the industries in which the Company participates as a whole; the effect of disruption in the business of suppliers, customers, facilities and shipping operations due to adverse weather, casualty events, equipment breakdowns, labor shortages, interruption in utility services, civil unrest, international conflicts (especially in light of Russia’s invasion of Ukraine), terrorist activities or other causes; changes in customer demand, inventories, spending patterns, product choices, and supplier choices; risks associated with doing business internationally, including economic, political and social instability (especially in light of Russia’s invasion of Ukraine), foreign currency exchange rate exposure and the acceptance of the Company’s products in global markets; the ability to improve and maintain processes and business practices to keep pace with the economic, competitive and technological environment; the effect of inflation, interest rate increases and economic recession, which may negatively impact the Company’s operations and financial results; deviation of actual results from estimates and/or assumptions used by the Company in the application of its significant accounting policies; the level of imports and import prices in the Company’s markets; the impact of environmental laws and regulations or the actions of the United States Environmental Protection Agency or similar regulators which increase costs or limit the Company’s ability to use or sell certain products; the impact of increasing environmental, greenhouse gas emission and sustainability regulations and considerations; the impact of judicial rulings and governmental regulations, both in the United States and abroad, including those adopted by the United States Securities and Exchange Commission and other governmental agencies as contemplated by the Coronavirus Aid, Relief and Economic Security (CARES) Act, the Consolidated Appropriations Act, 2021, the American Rescue Plan Act of 2021, and the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010; the effect of healthcare laws in the United States and potential changes for such laws, especially in light of the COVID-19 pandemic, which may increase the Company’s healthcare and other costs and negatively impact the Company’s operations and financial results; the effects of tax laws in the United States and potential changes for such laws, which may increase the Company’s costs and negatively impact the Company’s operations and financial results; cyber security risks; the effects of privacy and information security laws and standards; and other risks described from time to time in the Company’s filings with the United States Securities and Exchange Commission, including those described in “Part I – Item 1A. – Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2024.

Forward-looking statements should be construed in the light of such risks. The Company notes these factors for investors as contemplated by the Act. It is impossible to predict or identify all potential risk factors. Consequently, readers should not consider the foregoing list to be a complete set of all potential risks and uncertainties. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. The Company does not undertake, and hereby disclaims, any obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

Sonya L. Higginbotham



Senior Vice President

Chief of Corporate Affairs, Communications and Sustainability

614.438.7391

[email protected]

Marcus A. Rogier



Treasurer and Investor Relations Officer

614.840.4663

[email protected]

200 West Old Wilson Bridge Rd.

Columbus, Ohio 43085

WorthingtonEnterprises.com

A photo accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/34f20317-2c3c-479f-8d60-ccecb51df677

WOODS CROSS, Utah, June 19, 2025 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or “the Company”), an integrated energy solutions company committed to revolutionizing the waste asphalt shingle recycling industry, today announced that it will host a live investor webinar on

Thursday, June 26 at 11:00 a.m. PDT / 2:00 p.m. EDT.

The webinar will provide a strategic overview of the Company’s recent milestones and outline how these developments support Sky Quarry’s broader growth plan. Topics will include:

• 
  Utah Permit Update
  
  : How the application moves Sky Quarry closer to commercializing its PR Spring site as part of a scalable waste-to-energy strategy
• 
  Strategic Partnerships
  
  : The role of non-binding letters of intent with Southwind RAS, Right Way Roofing, and R & R Solutions in securing regional feedstock and siting modular units
• 
  Refinery Capacity Planning:
  
  How Sky Quarry’s plans to increase throughput at the Foreland Refinery could strengthen regional fuel supply and unlock future revenue opportunities
• 
  Emerging Market Tailwinds:
  
  How tightening fuel supplies in California are creating strong demand signals for Sky Quarry’s clean fuel strategy

The webinar will feature Sky Quarry executives David Sealock, Chairman and CEO, and Marcus Laun, EVP and Director, and will be moderated by Lloyd MacNeil, a partner at Troutman Pepper and a project finance attorney specializing in energy infrastructure.

The presentation will be followed by a live Q&A. Attendees are encouraged to submit questions in advance by emailing [email protected].

Registration is open to all investors, industry partners, and media.

To register for the webinar, please click here.


Space is limited, so early registration is encouraged.

About Sky Quarry Inc.

Sky Quarry Inc. (NASDAQ:SKYQ) and its subsidiaries are, collectively, an oil production, refining, and a development-stage environmental remediation company formed to deploy technologies to facilitate the recycling of waste asphalt shingles and remediation of oil-saturated sands and soils. Our waste-to-energy mission is to repurpose and upcycle millions of tons of asphalt shingle waste, diverting them from landfills. By doing so, we can contribute to improved waste management, promote resource efficiency, conserve natural resources, and reduce environmental impact. For more information, please visit


skyquarry.com


.

Forward-Looking Statements

This press release may include ”forward-looking statements.” All statements pertaining to our future financial and/or operating results, future events, or future developments may constitute forward-looking statements. The statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” or words of similar meaning. Such statements are based on the current expectations and certain assumptions of our management, of which many are beyond our control. These are subject to a number of risks, uncertainties, and factors, including but not limited to those described in our disclosures. Should one or more of these risks or uncertainties materialize or should underlying expectations not occur or assumptions prove incorrect, actual results, performance, or our achievements may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. We neither intend, nor assume any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated. You are urged to carefully review and consider any cautionary statements and the Company’s other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Company’s Form 10-K as filed with the SEC on March 31, 2025, as well as the Company’s Form 10-Q as filed with the SEC on May 15, 2025. Forward-looking statements speak only as of the date of the document in which they are contained.

Investor Relations


Jennifer Standley


Director of Investor Relations



[email protected]

Company Website




www.skyquarry.com

SACRAMENTO,,Caif., June 19, 2025 (GLOBE NEWSWIRE) — Sysco Corporation announced today its collaboration with the MICHELIN Guide in California as the official wholesale food distributor for one of the world’s most prestigious culinary events.

This partnership will be celebrated at the 2025 MICHELIN Guide California Ceremony in Sacramento on June 25 and will showcase Sysco’s high-quality, premium products and culinary expertise.

The

MICHELIN Guide

is renowned for its coveted ratings and in-depth reviews of restaurants worldwide, representing the pinnacle of gastronomic achievement.

“We are delighted to partner with the MICHELIN Guide to honor chefs whose extraordinary culinary achievements bring families together, create lifelong memories and experiences and help bridge divides by connecting our world and our communities through a shared love of food,” said Steve Buer, region president of Sysco’s North California Region.

“We are excited to see some of our esteemed Sysco customers recognized with MICHELIN Stars or other distinctions as we together live the Sysco purpose of Connecting the World to Share Food and Care for One Another,” Buer added.

In addition to distribution and its industry-leading product range, Sysco provides culinary consultations and innovative solutions to elevate menu concepts for chefs to stand out in the ever-evolving restaurant industry.

As part of this partnership, Buer will present the MICHELIN Guide Young Chef Award at the June 25 ceremony. This award celebrates the vital role emerging culinary talent plays in shaping the future of the industry.

“It is an honor to present the Young Chef Award, which highlights the incredible passion, skill and determination of the next generation of chefs,” Buer said. “Sysco is committed to nurturing these rising stars, and providing them with innovative solutions, quality products and expert support so they can create inspirational, ground-breaking menus.”

This is Sysco’s third partnership with MICHELIN, following the inaugural MICHELIN Guide Texas Ceremony in

November 2024

. Sysco was also a partner in the

2025 MICHELIN Guide Florida Ceremony.

About Sysco


Sysco is the global leader in selling, marketing and distributing food and related products to customers who prepare meals away from home. This includes restaurants, healthcare and educational facilities, lodging establishments, entertainment venues, and more. Sysco operates 340 distribution centers, in over 10 countries, with 76,000 colleagues serving approximately 730,000 customer locations. The company generated sales of more than $78 billion in fiscal year 2024 that ended June 29, 2024

.

As the world’s largest food-away-from-home distributor, Sysco offers customized supply chain solutions, bespoke specialty product offerings, and culinary support to drive customers to innovate and optimize their operations. We act as a trusted business partner to our customers, helping them grow through our industry-leading portfolio that includes fresh produce, premium proteins, specialty products, sustainably focused items, equipment and supplies, and innovative culinary solutions.

For more information, visit

www.sysco.com.

For important news and key information for Sysco investors, visit the Investor Relations section of the company’s website at

investors.sysco.com

.

SYY-NEWS

For more information contact:

Media Contact

Cassandra Mauel


[email protected]



[email protected]

HAMILTON, BERMUDA, June 19, 2025 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announces that it has entered into an agreement to acquire a VLCC built in 2018 at Hyundai Heavy Industries (HHI), for $107 million. The vessel is scheduled to deliver towards the end of the third quarter of 2025. The acquisition will be financed through the Company’s available liquidity and projected mortgage debt. The vessel was built to a high specification by its current owner and is fitted with an exhaust gas cleaning system. The acquisition will improve DHT’s age profile and will further improve the DHT fleet’s efficiency metrics.

DHT’s President & CEO, Svein Moxnes Harfjeld, comments: “We are always looking for opportunities with the intent of improving earnings per share for our shareholders. This is a sister of vessels built by us in 2018, a design with large carrying capacity and premium earning capabilities, well suited for the trading patterns of our key customers. We believe this to be a fitting addition to our fleet, replacing some of the earnings capacity that has been divested this year, delivering into a market with attractive prospects.”

About DHT Holdings, Inc.


DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our wholly owned management companies in Monaco, Norway, Singapore, and India. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations and customer service; our quality ships; our prudent capital structure that promotes staying power through the business cycles; our fleet employment with a combination of market exposure and fixed income contracts; our disciplined capital allocation strategy through cash dividends, investments in vessels, debt prepayments and share buybacks; and our transparent corporate structure maintaining a high level of integrity and corporate governance. For further information please visit

www.dhtankers.com

.

Forward Looking Statements


This press release contains certain forward-looking statements and information relating to the Company that are based on beliefs of the Company’s management as well as assumptions, expectations, projections, intentions and beliefs about future events. When used in this document, words such as “believe,” “intend,” “anticipate,” “estimate,” “project,” “forecast,” “plan,” “potential,” “will,” “may,” “should” and “expect” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. These statements reflect the Company’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent the Company’s estimates and assumptions only as of the date of this press release and are not intended to give any assurance as to future results. For a detailed discussion of the risk factors that might cause future results to differ, please refer to the Company’s Annual Report on Form 20-F, filed with the SEC on March 20, 2025.

The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur, and the Company’s actual results could differ materially from those anticipated in these forward-looking statements.

Contact:


Laila C. Halvorsen, CFO

Phone: +1 441 295 1422 and +47 984 39 935

E-mail: [email protected]

HONG KONG, June 19, 2025 (GLOBE NEWSWIRE) — At Super AI, Asia’s largest AI event held in Singapore,

GPTBots.ai

emerged as a highlight among enterprise AI platforms. The event brought together global industry leaders, innovators, and decision-makers, all seeking practical, scalable AI solutions to accelerate digital transformation and maintain a competitive edge.

Spotlighting Real Enterprise Needs


Throughout the exhibition, GPTBots engaged with top-tier clients whose needs reflected the region’s most urgent business trends:

• 
  Banking:
  
  The bank’s corporate division sought AI assistants for their sales teams, aiming to automatically monitor client news, uncover hidden business opportunities, and intelligently match these with relevant internal products. This approach enables more timely, data-driven, and personalized client engagement—helping banks stay ahead in a dynamic market.
• 
  Consulting:
  
  A leading global consulting firm explored GPTBots to automate customer service, reduce operational costs, and maintain high-quality client support. Their goal was to leverage AI to handle routine inquiries, freeing up human experts for more complex, value-added tasks.
• 
  Hospitality:
  
  A major hotel systems integrator was interested in deploying AI agents to manage guest inquiries—from bookings to room service—and to automatically generate daily operational reports for hotel management, streamlining both customer experience and internal operations.

How GPTBots Delivers


GPTBots’ enterprise-grade platform is designed for rapid, flexible deployment across industries:

• 
  Real-time Data Integration & Intelligent Matching:
  
  For banking, GPTBots enables AI agents to continuously scan news, financial data, and social media, surfacing actionable insights and matching them with the bank’s product suite.
• 
  Automated, 24/7 Customer Support:
  
  Consulting firms benefit from AI agents that resolve up to 90% of routine queries, ensuring consistent, high-quality service while reducing manual workload and costs.
• 
  Conversational AI & Automated Reporting:
  
  In hospitality, GPTBots powers seamless guest interactions and automates the creation and distribution of daily management reports, providing real-time operational insights.

Driving the Future of Enterprise AI in Asia


Super AI Singapore underscored the region’s growing demand for secure, adaptable, and industry-specific AI solutions. GPTBots is committed to bridging the gap between cutting-edge AI technology and real business value—helping enterprises unlock new opportunities, boost efficiency, and deliver exceptional customer experiences.

About GPTBots.ai


GPTBots.ai is an enterprise AI agent platform that empowers businesses to streamline operations, enhance customer experiences, and drive growth. Offering end-to-end AI solutions across customer service, knowledge search, data analysis, and lead generation, GPTBots enables enterprises to harness the full potential of AI with ease. With seamless integration into various systems, and support for scalable, secure deployments, GPTBots is dedicated to reducing costs, accelerating growth, and helping businesses thrive in the AI era.

To learn how GPTBots can accelerate your AI transformation, visit

gptbots.ai

.

Media Contact:

Tanya

Marketing Director


[email protected]

A photo accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/b67ba9d7-360b-4607-a8b5-fd37bff23e82

FALLS CHURCH, Va., June 19, 2025 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) announced today that its second quarter 2025 financial results will be posted on its investor relations website on Tuesday, July 22, 2025. Prior to the market opening, the company will issue an advisory release notifying the public of the availability of the complete and full text earnings release on the company’s website at

http://investor.northropgrumman.com

.

The company’s second quarter 2025 conference call will be held at 9:30 a.m. Eastern time, Tuesday, July 22, 2025. The conference call will be webcast live on Northrop Grumman’s website at

http://investor.northropgrumman.com

. Replays of the call will be available on the Northrop Grumman website for a limited time. Presentations may be supplemented by a series of slides appearing on the company’s investor relations home page.

Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared purpose to solve our customers’ toughest problems, our employees define possible every day.

This press release was published by a CLEAR® Verified individual.

GREENWICH, Conn., June 19, 2025 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced that the UK Competition and Markets Authority (CMA) has cleared GXO’s acquisition of Wincanton subject to the divestment of a small number of Wincanton grocery contracts in the UK, and that integration will be permitted with the vast majority of the Wincanton business once certain administrative conditions are met. The company also announced today that it is raising full-year guidance on organic revenue growth, adjusted EBITDA and adjusted diluted EPS.

Malcolm Wilson, chief executive officer of GXO, said, “We are pleased to have the UK regulatory review concluded and are excited to bring the two businesses together. The combination of GXO and Wincanton will enhance GXO’s offering for customers across the UK and Ireland and bring presence in strategic verticals that will serve as a springboard for growth. We are well positioned to move forward swiftly and look forward to welcoming the Wincanton team to GXO.”

Integration is expected to commence in the third quarter and the teams are permitted to collaborate on specified ongoing aerospace and defense tenders in the UK effective immediately. No further regulatory reviews are required.

Updated Full-Year 2025 Guidance

“Across our operations, we are seeing better than expected volumes and accelerated productivity gains in existing operations and new start-ups,” added Wilson. “Coupled with greater clarity on the timing of synergy benefits from the Wincanton acquisition, we are pleased to raise our full-year guidance, reflecting the resilience and visibility of our model and our diversification across geographies and verticals.”

Updated full-year 2025 guidance

¹

includes expected synergies of the Wincanton acquisition which remains subject to integration commencing in the third quarter:

• Organic revenue growth
  
  ²
  
  of 3.5% to 6.5% (
  
  up from 3% to 6%);
  
• Adjusted EBITDA
  
  ²
  
  of $860 million to $880 million
  
  (up from $840 million to $860 million);
  
• Adjusted diluted EPS
  
  ²
  
  of $2.43 to $2.63 (
  
  up from $2.40 to $2.60);
  
  and
• Adjusted EBITDA to free cash flow conversion
  
  ²
  
  of 25% to 35%
  
  (unchanged).
  

About GXO

GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has more than 150,000 team members across more than 1,000 facilities totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit

GXO.com

for more information and connect with GXO on

LinkedIn

,

X

,

Facebook

,

Instagram

and

YouTube

.

Non-GAAP Financial Measures

GXO’s non-GAAP financial measures in this press release include: adjusted earnings before interest, taxes, depreciation and amortization (“adjusted EBITDA”), adjusted earnings per share (diluted) (“adjusted EPS”), free cash flow conversion and organic revenue growth.

We believe that the above adjusted financial measures facilitate analysis of our ongoing business operations because they exclude items that may not be reflective of, or are unrelated to, GXO’s core operating performance, and may assist investors with comparisons to prior periods and assessing trends in our underlying businesses. Other companies may calculate these non-GAAP financial measures differently, and therefore our measures may not be comparable to similarly titled measures used by other companies. GXO’s non-GAAP financial measures should only be used as supplemental measures of our operating performance.

Adjusted EBITDA and adjusted EPS include adjustments for transaction and integration costs, regulatory matters and litigation expenses as well as restructuring costs and other adjustments. Transaction and integration adjustments are generally incremental costs that result from an actual or planned acquisition, divestiture or spin-off and may include transaction costs, consulting fees, retention awards, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities), and certain costs related to integrating and separating IT systems. Regulatory matters and litigation expenses primarily relate to the settlement of ongoing regulatory and legal matters. Restructuring costs primarily relate to severance costs associated with business optimization initiatives.

We believe that adjusted EBITDA improves comparability from period to period by removing the impact of our capital structure (interest expense), asset base (depreciation and amortization), tax impacts and other adjustments, which management has determined are not reflective of core operating activities and thereby assist investors with assessing trends in our underlying businesses.

We believe that organic revenue growth is an important measure because it excludes the impact of revenue from acquired businesses and foreign currency exchange rate fluctuations.

We believe that adjusted EPS improves the comparability of our operating results from period to period by removing the impact of certain costs and gains, which management has determined are not reflective of our core operating activities, including amortization of intangible assets acquired.

We believe that free cash flow conversion is an important measures of our ability to repay maturing debt or fund other uses of capital that we believe will enhance stockholder value. We calculate free cash flow conversion as free cash flow divided by adjusted EBITDA, expressed as a percentage.

Management uses these non-GAAP financial measures in making financial, operating and planning decisions and evaluating GXO’s ongoing performance.

With respect to our financial targets for full-year 2025 organic revenue growth, adjusted EBITDA, adjusted diluted EPS, and free cash flow conversion, a reconciliation of these non-GAAP measures to the corresponding GAAP measures is not available without unreasonable effort due to the variability and complexity of the reconciling items described above that we exclude from these non-GAAP target measures. The variability of these items may have a significant impact on our future GAAP financial results and, as a result, we are unable to prepare the forward-looking statements of income and cash flows prepared in accordance with GAAP, that would be required to produce such a reconciliation.

Forward looking statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements, including our full-year 2025 guidance of organic revenue growth, adjusted EBITDA, adjusted diluted EPS and free cash flow conversion. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by the company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors the company believes are appropriate in the circumstances.

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause or contribute to a material difference include, but are not limited to, the risks discussed in our filings with the SEC and the following: economic conditions generally; supply chain challenges, including labor shortages; competition and pricing pressures; our ability to align our investments in capital assets, including equipment, service centers and warehouses, to our respective customers’ demands; our ability to successfully integrate and realize anticipated benefits, synergies, cost savings and profit improvement opportunities with respect to acquired companies, including the acquisition of Wincanton; acquisitions may be unsuccessful or result in other risks or developments that adversely affect our financial condition and results; our ability to develop and implement suitable information technology systems and prevent failures in or breaches of such systems; our indebtedness; our ability to raise debt and equity capital; litigation; labor matters, including our ability to manage its subcontractors, and risks associated with labor disputes at our customers’ facilities and efforts by labor organizations to organize its employees; risks associated with defined benefit plans for our current and former employees; our ability to attract or retain necessary talent; the increased costs associated with labor; fluctuations in currency exchange rates; fluctuations in fixed and floating interest rates; fluctuations in customer confidence and spending; issues related to our intellectual property rights; governmental regulation, including environmental laws, trade compliance laws, as well as changes in international trade policies and tax regimes; governmental or political actions, including the United Kingdom’s exit from the European Union; natural disasters, terrorist attacks or similar incidents; damage to our reputation; a material disruption of our operations; the inability to achieve the level of revenue growth, cash generation, cost savings, improvement in profitability and margins, fiscal discipline, or strengthening of competitiveness and operations anticipated or targeted; failure in properly handling the inventory of our customers; the impact of potential cyber-attacks and information technology or data security breaches; and the inability to implement technology initiatives or business systems successfully; our ability to achieve Environmental, Social and Governance goals; and a determination by the IRS that the distribution or certain related spin-off transactions should be treated as taxable transactions. Other unknown or unpredictable factors could cause actual results to differ materially from those in the forward-looking statements. Such forward-looking statements should therefore be construed in the light of such factors.

All forward-looking statements set forth in this release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Forward-looking statements set forth in this release speak only as of the date hereof, and we do not undertake any obligation to update forward-looking statements to reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events, except to the extent required by law.

Media contact


Matthew Schmidt

+1 203-307-2809

[email protected]

Investor contact


Kristine Kubacki, CFA

+1 203-769-7206

[email protected]

IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott’s future dual glucose-ketone sensor in the U.S.

The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. With the iLet, people living with diabetes can achieve excellent clinical outcomes without the burden of carb counting* or manual insulin correction calculations. The system currently supports Abbott’s FreeStyle Libre

^®

3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market.

“This integration holds great promise for further enhancing real-time decision-making support for people living with diabetes,” said Sean Saint, President and CEO of Beta Bionics. “As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott’s future dual glucose-ketone sensor as soon as it becomes commercially available.”

*User must be carb aware

About Beta Bionics


Beta Bionics is a commercial-stage medical technology company dedicated to simplifying diabetes management and improving outcomes for people requiring insulin therapy. By leveraging advanced adaptive algorithms, Beta Bionics has developed the iLet

^®

Bionic Pancreas—the first FDA-cleared insulin delivery device with a fully autonomous insulin dosing algorithm. Designed to significantly enhance health outcomes and quality of life across a broad spectrum of individuals with diabetes, the iLet sets a new standard in diabetes care. For more information, visit

www.betabionics.com

.

Important Safety Information


Product for prescription only. For important safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

Investor Relations Contact:




[email protected]

Media and Public Relations Contact:




[email protected]

Strengthens Final-Mile Carrier Capabilities

WATERLOO, Ontario and ATLANTA, June 19, 2025 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX: DSG) (Nasdaq: DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired PackageRoute, a leading provider of final-mile carrier solutions.

Based in the US, PackageRoute’s mission is to simplify and optimize the daily operations of final-mile carriers. The company offers a mobile and web-based platform that provides real-time visibility into package deliveries, route optimization, and fleet management. PackageRoute’s software integrates seamlessly with pickup and delivery data, enabling contractors and drivers to make better-informed decisions and operate more efficiently.

“PackageRoute works primarily with subcontracted delivery service providers working as agents for larger carriers,” said James Wee, General Manager of Routing, Mobile and Telematics at Descartes. “We believe PackageRoute customers can get substantial value from our integrated Descartes GroundCloud routing, safety and compliance solutions.”

Descartes GroundCloud helps ensure seamless operations, end-to-end visibility, and standards of safety and compliance are met, including helping final-mile carriers comply with the various safety mandates of large transportation brands.

“We continue to invest in solutions that help final-mile carriers deliver shipments safely and efficiently,” said Edward J. Ryan, Descartes’ CEO. “We’re thrilled to welcome PackageRoute’s customers, partners and team of domain experts into the Descartes family.”

PackageRoute is headquartered in Sammamish, WA. Descartes acquired PackageRoute for approximately US $2 million, satisfied from cash on hand.

About Descartes Systems Group


Descartes is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, security, and sustainability of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, track and help improve the safety, performance and compliance of delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at

www.descartes.com

, and connect with us on

LinkedIn

and

X (Twitter)

.

Descartes Investor Contact


Laurie McCauley

(519) 746-2969



[email protected]

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ acquisition of PackageRoute and its solution offerings; the potential to provide customers with final-mile carrier solutions; other potential benefits derived from the acquisition and PackageRoute’s solution offerings; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the expected future performance of the PackageRoute business based on its historical and projected performance as well as the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes’ most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

HOUSTON, June 19, 2025 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (“Orion” or the “Company”), a leading specialty construction company, today announced new Marine and Concrete awards for a total value of approximately $100 million. In addition, Orion’s Chief Executive Officer and General Counsel were honored with executive leadership awards.

Management Commentary

“We are proud to be recognized with new contract awards that reflect the trust our partners place in us. These achievements are a testament to the strength of our team, our commitment to the highest safety standards, and the progress we are making in expanding our business development pipeline,” said Travis Boone, Chief Executive Officer of Orion Group Holdings, Inc. “Our strong delivery and consistent execution have enabled us to successfully expand our client relationships and Port Tampa Bay is a good example. For many years, we have been their longstanding partner for maintenance dredging and new construction projects. We are pleased to play a role in their expansion initiatives aimed at enhancing the port’s capacity and efficiency.”

Boone continued, “In our Concrete business, we continue to see strong demand, supported by the next phase of a large data center project and several projects in our home state. With our strong reputation and robust pipeline, we are well positioned for continued growth.”

New Contracts

Orion’s Marine business recently secured $67 million in new wins. For Weyerhaeuser Company, Orion Marine was awarded the Longview Export Dock Replacement project. This work involves removing the existing timber Berth A structure and replacing it with a new concrete structure supported by large-diameter steel pipe piles. The project is expected to last 12 months and will begin in the third quarter of 2025.

In addition, Orion Marine won two projects with the Port of Tampa Bay. The first award is a 3-year maintenance dredging contract for the Port, estimated to begin work in September 2025. The second contract is for the Port Redwing Berth 301 Wharf project – a crucial project given the rapid population growth in the Tampa Bay region and the increasing demand for construction and bulk materials.

Orion Concrete won $33 million in new contract awards, including a data center project in Iowa, the Harris County Sheriff’s Office Complex in Houston as a subcontractor for Durotech, Inc., and the foundation of a cold storage facility for U.S. Foods. These projects will commence in the third quarter of 2025 with an estimated duration of one year. In addition, the Company was recently awarded a contract with the City of Ingleside wastewater treatment plant as a subcontractor to Associated Construction Partners. This project is expected to begin in December of 2025 with a duration of 12 months.

Executive Leadership Awards

Orion’s executive leadership team was recently recognized for outstanding achievements. Travis Boone, Orion’s Chief Executive Officer, was named a finalist for the EY Entrepreneur of The Year® 2025 Gulf South Award, presented by Ernst & Young LLP. This prestigious recognition honors visionary business leaders who are driving innovation and growth across industries.

Chip Earle, Orion’s General Counsel, won the Lexology North America Award for in-house general counsel in the construction industry. In association with the Association of Corporate Counsel, Lexology recognizes the outstanding achievements of the world’s leading legal practitioners across various practice areas and sectors.

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas.

https://www.oriongroupholdingsinc.com

.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the “safe harbor” provisions of Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, of which provisions the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, guidance, outlook, assumptions, or goals. In particular, statements regarding our pipeline of opportunities, financial guidance and future operations or results, including those set forth in this press release, and any other statement, express or implied, concerning financial guidance or future operating results or the future generation of or ability to generate revenues, income, net income, gross profit, EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, or cash flow, including to service debt or maintain compliance with debt covenants, and including any estimates, guidance, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward-looking statements also include project award announcements, estimated project start dates, ramp-up of contract activity and contract options, which may or may not be awarded in the future. Forward-looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints, and any potential contract options which may or may not be awarded in the future, and are at the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. Considering these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise, except as required by law.

Please refer to the Company’s 2024 Annual Report on Form 10-K, filed on March 5, 2025 which is available on its website at

www.oriongroupholdingsinc.com

or at the SEC’s website at

www.sec.gov

, and filings and press releases subsequent to such Annual Report on Form 10-K for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Contact:

Margaret Boyce

Orion Group Holdings, Inc.


[email protected]


312-402-6980

Source: Orion Group Holdings, Inc.

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it received notification (the “Acceptance Letter”) from the New York Stock Exchange (“NYSE”) that the NYSE has accepted the Company’s previously-submitted plan (the “Plan”) to regain compliance with the NYSE’s continued listing standards relating to minimum market capitalization and stockholders’ equity.

In the Acceptance Letter, the NYSE granted the Company an 18-month period from the Company’s receipt of the NYSE’s Notice of Noncompliance dated March 26, 2025 (the “Plan Period”) to regain compliance with the continued listing standards. As part of the Plan, the Company is required to provide the NYSE quarterly updates regarding its progress towards the goals and initiatives in the Plan.

The Company expects its stock will continue to be listed on the NYSE during the Plan Period, subject to the Company adherence to the Plan and compliance with other applicable NYSE continued listing standards. The Company’s receipt of such notification from the NYSE does not affect the Company’s business, operations or reporting requirements with the U.S. Securities and Exchange Commission.

Forward-Looking Statements


This press release contains, and oral statements made from time to time by our representatives may contain, “forward-looking statements.” Forward-looking statements include statements identified by words such as “could,” “may,” “might,” “will,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the Company’s ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSE’s acceptance of such plan; the Company’s ability to execute such plan and to continue to comply with applicable listing standards within the available cure period; risks arising from the potential suspension of trading of the Company’s common stock on the NYSE; regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks regarding our ability to manage inventory or anticipate consumer demand; changes in consumer confidence and spending; our competitive environment; our failure to open new profitable stores or successfully enter new markets and other factors set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Any forward-looking statement made in this report speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

About Annovis


Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit

www.annovisbio.com

and follow us on

LinkedIn

,

YouTube

, and

X

.

Contact Information:


Annovis Bio Inc.

101 Lindenwood Drive

Suite 225

Malvern, PA 19355


www.annovisbio.com

Investor Contact:


Alexander Morin, Ph.D.

Director, Strategic Communications

Annovis Bio


[email protected]

CHANTILLY, Va., June 19, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a $137 million ceiling value contract by the Defense Threat Reduction Agency (DTRA) for cyber operations. The single award was issued under the Assessment, Exercise, Modeling and Simulation, and Support (AEMSS) indefinite-delivery, indefinite-quantity (IDIQ) multiple award task order contract (MATOC) with a one-year base period of performance and four one-year option periods plus one six-month option period and is new work for the company. Parsons will provide specialized cyber operations capabilities including cyber assessments and subject matter experts supporting cyber operations, development, analysis, and research.

“Every day, Parsons’ skilled professionals and extensive cyber operations experience are empowering our customers to counter and mitigate threats to U.S. safety and security,” said Jon Moretta, President, Engineered Systems, for Parsons. “We have supported DTRA’s mission to prevent, reduce, and counter threats to national security for decades, and we remain committed to enhancing our nation’s readiness to combat cyber threats and protect citizens and critical infrastructure.”

This award is Parsons’ third task order under the AEMSS IDIQ MATOC and continues to grow the company’s work with DTRA. Previous task orders include work to identify and mitigate a broad spectrum of vulnerabilities and threats to mission critical facilities, and building partner nation capabilities to detect, interdict, and deter weapons of mass destruction and related items at land, air, and maritime ports of entry.

For decades, Parsons has supported cybersecurity operations worldwide with leading-edge technical innovations, mission planning and automation solutions, cyber threat intelligence, and advanced cyber threat hunting and incident response. The company’s experience spans national security missions and protecting critical infrastructure through tools and technology that enable a more secure and robust means to solve the toughest cyber challenges.

To learn more about Parsons’ global security and mission solutions, visit


Parsons.com/security-and-mission-solutions/


.

About Parsons:



Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and intelligence, space and missile defense, transportation, environmental remediation, urban development, and critical infrastructure. Please visit



parsons.com



and follow us on



LinkedIn



and



Facebook



to learn how we’re making an impact.

Forward-Looking Statements:



This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Registration Statement on Form S-1 and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this presentation that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so in connection with our ongoing requirements under federal securities laws.

Media Contact:

Jonathan Larry

+1 706.832.7330


[email protected]

Investor Relations Contact:

Dave Spille

+1 703.775.6191


[email protected]

Moomoo Australia and New Zealand chief executive officer Michael McCarthy.

SYDNEY, June 19, 2025 (GLOBE NEWSWIRE) — Investors want to open self-managed super funds, to invest in cryptocurrency, and make use of artificial intelligence, found investment platform moomoo Australia and New Zealand in its recent survey of share investors.

But a key finding was that the complexity and cost of opening a SMSF is stopping those interested in opening a fund from doing so.

SMSF complexity holds investors back

Moomoo aims to simplify the complex setup of SMSFs, which is why 24% of interested Australians say they haven’t opened a fund. At the same time, moomoo and its partners offer a transparent range of fees to reassure the 21% of people that cite costs as their reason for not opening a SMSF.

A key third reason interested Australians hold back from opening a SMSF is not knowing what to invest in (24%). So, moomoo is providing a broad range of news and content, including from SMSF experts, to help investors manage their super to deliver for the long term.

“There are clear, legitimate reasons that even those Australians familiar with share investing and interested in opening a self-managed super fund, haven’t done so. We answer these concerns head on with our trading account service, administration partner services, and sophisticated investing resources,” says moomoo Australia and New Zealand chief executive officer Michael McCarthy.

Not only can investors use moomoo to set up a SMSF trading account, but also our partners for investment guidance, and other services including fund setup, rollovers, reporting, compliance and ongoing management.

They want to make use of artificial intelligence

Most Australian share investors (67%) would use artificial intelligence in their SMSF investing, found moomoo Australia.

Specifically, survey results show a third would use AI for their SMSF investment strategy, while 37% would use it to analyse individual investments. A third would also use AI to help manage the fund, and almost 30% to meet compliance requirements. Just over a quarter of respondents would use AI tools to meet all four needs.

“Australians’ recognition of the power of AI to lessen the burden of managing a SMSF is particularly interesting given that they cite the complication of opening a SMSF as a leading reason for not doing so,” explains Mr McCarthy.

“This need comes at the right time for moomoo, with our AI assistant launching this month. Combined with the platform’s other AI-powered features, including our trend projection and market monitoring automation, we’re using the full power of artificial intelligence to really help investors make easier, smarter, more informed trades.”

An appetite for cryptocurrency

Australians interested in opening a SMSF are far more likely to trade Bitcoin than those who already own a self-managed super fund, found moomoo Australia.

Almost two thirds (60%) of those interested in SMSFs are either trading or want to trade cryptocurrencies, particularly Bitcoin (88%) and Ethereum (56%). Almost a third are interested in stablecoins and altcoins.

But for the more conservative current SMSF owners, just over half (55%) are trading crypto or would like to. And they’re far more diversified in their interest, with 40% trading or wanting to trade Bitcoin, a third focused on memecoins and a sizeable minority (27%) on stablecoins.

“There is strong investor interest in cryptocurrency. And the moomoo platform provides for them, with access to more than 26,000 securities across the Australian, US and Hong Kong markets, including a broad range of crypto-based stocks and exchange-traded funds,” says Mr McCarthy.

About the survey

Moomoo Australia surveyed 153 sharemarket investors experienced in trading and managing superannuation (independent of the moomoo platform). About one third of respondents held a self-managed super fund, with 22% interested in opening one.

Characteristics of those that own or would like to own a SMSF are quite similar. Generally, aged over 45, they work full time with a household income between $50,000 and $150,000. Those not yet running a SMSF have less share-trading experience (about one year) and are less confident in their investment knowledge (describing themselves as ‘intermediate’).

Australians that invest in shares and hold a self-managed super fund, or want to:

• are either intermediate (41%) or advanced (35%) in their level of investment knowledge
• believe their retirement balance can be up to $200,000 (23%), $500,000 (32%), $1m (26%)
• would use AI investing tools (67%), to strategise (33%) and analyse investments (37%)
• believe AI is great for SMSF reporting (37%), management (37%), but isn’t secure (31%).

Those that haven’t yet set up a SMSF:

• haven’t done so because they’re satisfied with their current fund (55%), see the process as too complex (23%) or don’t believe they have enough funds (23%)
• would want to invest in Australian stocks (76%), property (55%), crypto (39%), ETFs (30%)
• would not invest in crypto (36%), futures (24%), bonds (18%), non-US global stocks (18%).
  

About moomoo

Through moomoo, investors can access local and international markets, choosing from more than 26,000 shares and ETFs – more securities than most broking platforms in Australia – to shape their own retirement investment strategy. We’ve partnered with four administration service providers – Intello, Superannuation Warehouse, Just Superfund, SMSFai – to provide a one-stop service to clients.

Moomoo Australia

is a next-generation investment platform that integrates investment transactions, up-to-date news, real-time market data, and an active trading community. It offers investors access to securities across the Australian, United States and Hong Kong markets.

Moomoo is owned by Futu Holdings, a global fintech operation listed on the Nasdaq. It operates in seven world markets including Japan and the United States.

Media contact

(to arrange interviews and photos)

Moomoo Australia and New Zealand senior content manager Byron Smith, phone 0411 272 701, email

[email protected]

A photo accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/96e9e2b9-ad94-4bd6-aa93-c67fc0855d76

LOUDON, Tenn., June 18, 2025 (GLOBE NEWSWIRE) — Malibu Boats, the world’s best-selling wakeboat brand, is thrilled to announce the continuation of its long-standing partnership with


General Motors


, naming


Chevrolet


as the Official Vehicle Brand of Malibu Boats. This partnership reinforces Malibu Boats’ commitment to excellence and innovation, extending their exclusive collaboration with


GM Marine


for the vertical integration of the


Monsoon Line of engines


at the Malibu Boats Factory in Loudon, TN.

“GM’s partnership with Malibu Boats is a natural fit,” said Rachael Green, Sr VP, Operations & Engineering at Malibu Boats. “Malibu and GM share a commitment to using cutting-edge technology to empower our customers to create perfect memories on the water. Our long-standing partnership with GM currently allows us to build our top-of-line engines that power the best wakes & waves in the industry, and this enhanced partnership will only allow us to showcase this further across the nation.”

This partnership builds on the current long-standing relationship between Malibu Boats and GM’s engineering departments to develop and produce the Malibu Monsoon Line of engines — exclusive to Malibu and Axis Boats. Using proven GM engine blocks, the Malibu Engineering team designs and marinizes the engines in-house to meet the unique demands of boating with exclusive modifications that simplify maintenance, reduce corrosion, and offer unmatched performance, fuel economy, reliability and sound reduction.

Chevrolet is GM’s largest vehicle brand and sells the Silverado, Tahoe and Suburban – the popular vehicles of choice for boat owners across the country.

“We’re honored to be named the official vehicle brand of Malibu Boats,” said Amy Masica, director of marketing at Chevrolet. “Both our brands rely on GM’s reliable engines to get customers where they need to go – whether it be on land or on the water.”

Malibu’s partnership with GM Marine will continue to provide comprehensive support for Malibu’s premier initiatives throughout the year, including the Malibu Just Ride Tour, Malibu Rider Experience Series, VIP Factory Tour Experience, WakeFest TN, and various dealer-focused programs across the United States. This collaboration ensures that Malibu Boats remains at the forefront of the industry, delivering exceptional experiences and a perfect on-water experience to boating enthusiasts.

For more information, visit


www.malibuboats.com


and


https://poweredsolutions.gm.com


. Follow along on


Instagram


,


YouTube


, and


Facebook


. For more information on 2025 Chevrolet vehicles, visit


https://www.chevrolet.com/


.

General Motors

(NYSE:GM) is driving the future of transportation, leveraging advanced technology to build safer, smarter, and lower emission cars, trucks, and SUVs. GM’s Buick, Cadillac, Chevrolet, and GMC brands offer a broad portfolio of innovative gasoline-powered vehicles and the industry’s widest range of EVs, as we move to an all-electric future.

About Malibu Boats, Inc.

Malibu Boats, Inc. (NYSE:MBUU) is a leading designer, manufacturer and marketer of a diverse range of recreational powerboats, including performance sport, sterndrive and outboard boats. Malibu Boats, Inc. is the market leader in the performance sport boat category through its Malibu and Axis boat brands, the leader in the 20’ – 40’ segment of the sterndrive boat category through its Cobalt brand, and in a leading position in the saltwater fishing boat market with its Pursuit and Cobia offshore boats and Pathfinder, Maverick, and Hewes flats and bay boat brands. A pre-eminent innovator in the powerboat industry, Malibu Boats, Inc. designs products that appeal to an expanding range of recreational boaters, fisherman and water sports enthusiasts whose passion for boating is a key component of their active lifestyles. For more information, visit


www.malibuboats.com


,


www.axiswake.com


,


www.cobaltboats.com


,


www.pursuitboats.com


, or


www.maverickboatgroup.com


.

A photo accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/ce1e6b31-c394-43d2-bbcf-fecf1a062108

MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today launches Zest Insurance, a cutting-edge digital insurance platform tailored specifically for small and medium enterprises (SMEs) in Australia.

Zest Insurance represents a bold step forward in the digital transformation of SME insurance. It offers a seamless, fast and intuitive online experience backed by expert broker support. Designed to meet the evolving needs of modern business owners, Zest Insurance empowers SMEs to purchase, manage and renew their insurance policies entirely online.

James Baum, Head of Pacific, WTW says: “The launch of Zest Insurance comes at a pivotal time for the Australian SME market. With 97% of businesses having 20 or fewer employees, the platform is poised to serve a vast and growing segment of the market. Zest Insurance aims to bridge the gap between traditional insurance models and the digital expectations of modern SME owners.”

Brent Lehmann, Head of Commercial & Affinity, Pacific at Willis, adds: “SMEs are the backbone of the Australian economy, yet many still face outdated, complex processes when it comes to insurance. They increasingly demand convenience, speed and tailored insurance solutions. Zest Insurance is our answer to that challenge, bringing together digital convenience and trusted expertise in one powerful platform. It aims to make purchasing business insurance more straightforward for small business owners.”

The Australian SME market, valued at over AUD 9 billion in gross written premium, has been slower to adopt digital insurance solutions compared to global counterparts. Zest Insurance aims to close that gap by offering:

• 
  A fully digital customer journey
  
  – from insurance quote to bind, renewal, and policy management, all conducted online.
• 
  Industry-specific insurance solutions
  
  – with one dedicated insurer per industry to ensure tailored coverage to protect businesses.
• 
  User-friendly design
  
  – intuitive forms and interfaces built to enhance and simplify the customer experience.
• 
  Insurance broker support on demand
  
  – expert advice available when needed, ensuring confidence and clarity.

Zest Insurance will be available initially to businesses in the administration and support services industry, including bookkeepers, payroll services, management and marketing consultants, market research firms and more, with plans to expand industry offerings in future phases. Zest Insurance policies for this first industry will be exclusively underwritten by Chubb, a world leader in insurance.

James adds: “We’ve built Zest Insurance to be more than just a platform. It’s a new way of thinking about SME insurance. It’s about simplicity, transparency and putting the customer first. Together, we’re setting a new standard for SME insurance, starting in Australia.”

For more information, visit:

www.zestinsurance.com

.

About WTW

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance.

Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at wtwco.com.

Media contact

Clara Goh: +65 6958 2542


[email protected]

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) — AMC Networks Inc. (“AMC Networks” or the “Company”) (Nasdaq: AMCX) today announced that it has priced an offering of $400 million aggregate principal amount of 10.50% senior secured notes due 2032 (the “Notes”) in a private offering.

The Notes will be unconditionally guaranteed, on a joint and several basis, by each of AMC Networks’ existing and future domestic subsidiaries, subject to certain exceptions, on a senior secured basis.

AMC Networks expects to use the net proceeds from the offering of the Notes, together with cash on hand or other immediately available funds, to (i) fund its tender offer (the “Tender Offer”) to purchase for cash up to $450,000,000 aggregate principal amount of its outstanding 4.25% Senior Notes due 2029, (ii) pay related premiums, fees and expenses incurred in connection with the offering of the Notes and the Tender Offer, and (iii) repurchase or repay other corporate indebtedness.

AMC Networks is offering the Notes (and the related guarantees) pursuant to an exemption under the Securities Act of 1933, as amended (the “Securities Act”). The initial purchasers of the Notes will offer the Notes only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act or outside the United States to certain persons in reliance on Regulation S under the Securities Act. The Notes have not been and will not be registered under the Securities Act or under any state securities laws. Therefore, the Notes may not be offered or sold within the United States to, or for the account or benefit of, any United States person unless the offer or sale would qualify for a registration exemption from the Securities Act and applicable state securities laws.

This press release shall not constitute an offer to sell, the solicitation of an offer to buy or a notice of redemption for any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About AMC Networks


AMC Networks (Nasdaq: AMCX) is home to many of the greatest stories and characters in TV and film and the premier destination for passionate and engaged fan communities around the world. The Company creates and curates celebrated series and films across distinct brands and makes them available to audiences everywhere. Its portfolio includes targeted streaming services AMC+, Acorn TV, Shudder, Sundance Now, ALLBLK and HIDIVE; cable networks AMC, BBC AMERICA (which includes U.S. distribution and sales responsibilities for BBC News), IFC, SundanceTV and We TV; and film distribution labels Independent Film Company and RLJE Films. The Company also operates AMC Studios, its in-house studio, production and distribution operation behind acclaimed and fan-favorite original franchises including The Walking Dead Universe and the Anne Rice Immortal Universe; and AMC Networks International, its international programming business.

Forward-Looking Statements



This press release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the timing, terms and completion of the offering of the Notes, the anticipated use of proceeds from the offering of the Notes and the timing, terms and completion of the Tender Offer. Investors are cautioned that any such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results, developments or events may differ materially from those in the forward-looking statements as a result of various factors, including financial community perceptions of the Company and its business, operations, financial condition and the industries in which it operates and the factors described in the Company’s filings with the Securities and Exchange Commission, including the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained therein. The Company disclaims any obligation to update any forward-looking statements contained herein.

Contacts